ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Pres. Bill Clinton to Serve as Honorary Chair Of NBCC’s Breast Cancer Deadline 2020

November 16, 2012

FDA, Genentech Agree On Framework for Avastin Hearing June 28-29

April 8, 2011

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

March 25, 2011

NCI Bypass Budget An Underutilized Document and Ignored By MB; Deserves Attention Of Congress

January 20, 1989

CTI Files Appeal Over FDA’s Decision on Pixantrone

December 3, 2010

ODAC Votes for Marqibo Accelerated Approval

March 30, 2012